The Link between the Metabolic Syndrome and Cancer by Braun, Sandra et al.
Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
1003 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2011; 7(7):1003-1015 
Review 
The Link between the Metabolic Syndrome and Cancer  
Sandra Braun, Keren Bitton-Worms, Derek LeRoith 
  
Diabetes and Metabolism Clinical Research Center of Excellence, Legacy Heritage Clinical Research Institute at Rambam 
(LHCRIR), Haifa, Israel.  
 Corresponding author: Derek LeRoith, M.D., Ph.D., Director, Diabetes and Metabolism Clinical Research Center of Ex-
cellence, Legacy Heritage Clinical Research Institute at Rambam (LHCRIR). Tel: 972-4-854-1260. d_leroith@rambam.health. 
gov.il 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.06.16; Accepted: 2011.07.24; Published: 2011.08.16 
Abstract 
Since the incidence of the metabolic syndrome is on the rise in the western world, its co-
herence to cancer is becoming more apparent. In this review we discuss the different potential 
factors involved in the  increase of cancer in the metabolic syndrome including obesity, 
dyslipidemia and Type 2 Diabetes Mellitus (T2DM) as well as inflammation and hypoxia. We 
especially focus on the insulin and IGF systems with their intracellular signaling cascades 
mediated by different receptor subtypes, and suggest that they may play major roles in this 
process.  Understanding  the  mechanisms  involved will  be  helpful  in  developing  potential 
therapeutics. 
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Metabolic Syndrome 
The  metabolic  syndrome  and  its  concomitant 
diseases are a severe health problem world-wide and 
most  likely  will  gain  even  more  importance  in  the 
future since the prevalence of obesity is rising (1). The 
metabolic syndrome includes abdominal obesity, hy-
pertension,  dyslipidemia  and  hyperglycemia  and  is 
linked to insulin resistance and the development of 
diabetes mellitus as well as to nonalcoholic fatty liver 
disease (2). The Aerobic Center Longitudinal Study of 
33  230  cancer-free  men  revealed  an  up  to  56%  en-
hanced  risk  of  cancer  mortality  associated  with  the 
metabolic syndrome after 14 years of following-up (2). 
Also  other  studies  support  that  the  metabolic  syn-
drome, or its components, might play an important 
role in the etiology and progression of certain cancer 
types  and  a  worse  prognosis  for  some  cancers  (3). 
Obesity and diabetes, individually, have been associ-
ated with breast, endometrial, colorectal, pancreatic, 
hepatic and renal cancer (4-5).  
Obesity and Cancer 
Worldwide there are 1.1 billion overweight peo-
ple with a BMI between 25 kg/m2 and 30 kg/m2 and 
312 million with a BMI > 30 kg/m2 (6). Within the last 
four decades the prevalence of obese people in the US 
increased and is currently 66% of adults with a body 
mass index (BMI) > 25 kg/m2 and half of those have a 
BMI of > 30 kg/m2 (7). It was seen that obese patients 
tend  to  manifest  more  localized  tumors,  earlier  re-
lapse  and  a  diminished  overall  survival  (8).  The 
American  Cancer  Society  calculates  that  currently 
new cancer cases are in the order of 1.5 million with 
half a million cancer deaths per year, nearly one in 
five due to obesity (4, 9-10). A projection for the year 
2030  estimated  that  366  million  people  will  suffer 
from obesity and the accompanying Type 2 Diabetes 
Mellitus  (T2DM)  (11).  A  large  epidemiologic  study 
showed evidence for the association between obesity, 
T2DM and particular cancer types. The CPS II study 
revealed  a  significantly  enhanced  relative  risk  for 
colorectal  cancer  in  obese  people  (4).  This  risk  was 
maintained  even  after  adjusting  for  factors  such  as 
BMI,  family  history,  physical  activity,  smoking,  red 
meat  consumption,  hormone  and  aspirin  use  (12). 
Interestingly,  not  the  BMI  but  waist  circumference 
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seems  to  be  a  strong  predictor  of  colorectal  cancer 
(13). Furthermore, it has been shown that there is an 
association between obesity and cancer of the gastric 
cardia,  esophageal  adenocarcinoma  and  cholangio-
carcinoma (4). The tendency to develop these tumors 
was  ascribed  to  Barret´s  esophagus  caused  by  gas-
troesophageal reflux disease (GERD) (14), which ap-
pears to be common in obese people. Another study 
also linked a high BMI in both genders to an enhanced 
risk  of  colorectal,  esophageal  and  kidney  cancer  as 
well  as  the  non-Hodgkins  lymphoma  and  multiple 
myeloma (4, 15). Multiple myeloma and large B cell 
lymphoma were especially linked to obesity in men 
(16-17). Also breast cancer has been linked to obesity 
in  postmenopausal  women  (4).  For  obese,  diabetic, 
postmenopausal  women  there  exists  an  augmented 
risk  especially  for  estrogen  receptor-positive  breast 
cancer (5). Obese women were found to display many 
fold higher estrogen levels than normal-weight indi-
viduals.  After  adjusting  for  known  risk  factors  for 
breast cancer like family history, use of hormones or 
menopausal  status,  a  positive  correlation  between 
breast cancer mortality and a BMI > 25 kg/m2 was 
found.  Female  patients  with  a  BMI  >  40  kg/m2 
showed  twice  the  risk  of  slim  women  to  develop 
breast  cancer  (4).  Approximately  30-50%  of  deaths 
caused by breast cancer are due to obesity and over-
weight (18). It is hypothesized that the increased en-
dogenous estrogen level in obese women plays a key 
role in both the postmenopausal breast and endome-
trial  cancer  incidence  (4).  Compared  to  lean, 
non-diabetic individual, the risk of obese persons to 
develop endometrial cancer rises from 2-fold to 6-fold 
if they develop T2DM (19). Cervical adenocarcinoma 
has also been associated with obesity (20). Regarding 
the association between obesity and prostate cancer 
the data in the literature is inconsistent (5).  
 
Dyslipidemia and Cancer 
Dyslipidemia  includes  low  high-density- 
lipoprotein  cholesterol  (HDL-C),  high 
low-density-lipoprotein cholesterol (LDL-C) and high 
serum  triglycerides  (TG)  levels.  Low  HDL-C  serum 
levels were associated with lung cancer incidence as 
well as the Non-Hodgkin lymphoma (NHL) and was 
suggested to be a marker for increased breast cancer 
risk  in  pre-menopausal  as  well  as  post-menopausal 
women, since it might reflect an unfavorable hormo-
nal profile with particularly increased estrogen levels 
especially  in  obese  women  (3,  21-24).  Furthermore, 
high serum levels of total cholesterol and TG raise the 
risk of prostate and post-menopausal breast cancer (3, 
25-26). Inconsistent with these data, low LDL-C serum 
levels were also linked to an 15-fold increased risk of 
developing hematological cancer (3). 
 
Table 1: Cancer association with obesity, diabetes and 
obesity or dyslipidemia. 
 
 
Diabetes and Cancer 
Several studies analyzed the association between 
diabetes and cancer development. A large prospective 
study in the US followed a cohort of 467,922 men and 
588,321  women  for  16  years  who  had  no  reported 
history of cancer. After this long follow-up, the results 
showed that independent of a high body mass, T2DM 
acts as a predictor of mortality from cancer of the co-
lon, pancreas, female breast, male liver and bladder 
(27).  An  increased  incidence  of  colorectal  cancer  in 
diabetic patients independent of obesity is supported 
by  the  Physician  Health  Study  (28).  Another  study 
from Italy observed a slight rise of cancer mortality in 
diabetic  patients  which  achieved  statistical  signifi-
cance in women but not in men. The mortality of di-
abetic women was mainly caused by pancreatic and 
breast tumors in which the mortality of breast cancer 
was especially evident in obese women with diabetes 
(29).  Even  though  there  is  a  strong  association  be-
tween pancreatic cancer and diabetes, it is still a sub-
ject of speculation if diabetes is the outcome of the 
pancreatic  cancer  or  vice  versa.  But  one  percent  of 
newly  diagnosed  diabetic  patients  >50  years  will 
contract pancreatic cancer within three years (5). The 
main risk factors for pancreatic and lung cancer are 
considered  to  be  cigarette  smoking.  Lung  cancer  in 
most studies did not show any connection to diabetes, 
although a Korean study revealed an enhanced risk of Int. J. Biol. Sci. 2011, 7 
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lung cancer in non-smoking, diabetic women (10). An 
augmented risk for estrogen receptor-positive breast 
cancer was found in postmenopausal, obese and dia-
betic women (5). However, diabetes was not associ-
ated with increased breast cancer in premenopausal 
women (30). Regarding diabetes and prostate cancer 
incidence and mortality, most studies suggest an in-
verse connection (5). 
Potential Causal Factors 
Some studies suggest a link between obesity, in-
flammation and insulin resistance in patients with the 
metabolic  syndrome  potentially  caused  by  adipose 
tissue hypoxemia. The adipose tissue of obese patients 
show  inflammation  characterized  by  elevated  in-
flammatory cytokines in plasma and adipose tissue as 
well as macrophage infiltration and activation in the 
adipose tissue. Inflammation by means of TNF- is 
able to contribute to insulin resistance by intervening 
in  the  intracellular  signalling  cascade  of  insulin 
(31-32).  Especially  systemically  elevated  free  fatty 
acids (FFA) and decreased adiponectin levels found in 
the blood of obese people might contribute to insulin 
resistance since FFA and inflammatory cytokines are 
capable  and  thus  of  aggravate  insulin  resistance. 
Furthermore, the transcriptional activity of the nucle-
ar  factor  PPAR  plays  an  important  role  in  insulin 
sensitivity. TNFα and IL-1, both inflammatory medi-
ators induced by NF-B, and may inhibit PPAR, that 
in turn might promote insulin resistance (31).  
Another interesting aspect is the role of the IGF-1 
receptor, which is expressed by almost all normal and 
transformed cells. Data from several studies suggest 
that IGF-1 and the IGF-1R are necessary for the nor-
mal  growth  and  development  of  cells  (33-34).  But 
IGF-1R and IR have been found to be overexpressed 
in cancer cells (35-36). The PI3K signaling cascade is a 
major  pathway  of  the  IGF-1R  and  IR  (34,  37)  and 
commenly deregulated in cancer cells (38-39). In the 
1980´s  the  Middle  T  antigen  of  Polyoma  virus  was 
found to mediate its oncogenic activity by inducing 
PI3K. Thus, it is conceivable that mutations in tumor 
suppressor genes resulting in a dysregulation of insu-
lin and IGF-1 signaling pathways, might lead to can-
cer development. It is of special interest to investigate 
the role of signaling through IR and IGF-1 in diabetes 
and  obesity  in  regards  to  cancer  because  signaling 
through  IR  and  IGF-1R  is  increased  in  hyperinsu-
linemia (50). It is well known that a large number of 
tumor types and cancer-derived cells overexpress the 
IGF-1  receptor,  which  mediates  mitogenic  effects. 
Some tumors, like squamous carcinoma and small cell 
lung cancer produce high levels of IGF-1 themselves. 
However, the main source of IGF-1 seems to be the 
liver  since  it  provides  75%  of  the  circulating  IGF-1 
(40). Hyperinsulinemia was shown to even increase 
the IGF-1 production of the liver (41). In contrast to 
the mentioned cancer types above, breast cancer does 
not  generally  produce  IGF-1  but  does  express  and 
secrete small amounts of IGF-2. Furthermore, estro-
gen was found to induce IGF-1 receptor expression in 
estrogen receptor-positive breast cancer cell lines (37). 
Since IGF-2 is produced by adult human tissues but 
not by the adult tissue of the mouse and mice with an 
IGF-1 null mutation in the liver did not demonstrate 
any reduction in somatic growth (40), it is not clear for 
now whether the hepatic- or the non-hepatic IGF-1 or 
IGF-2 plays the primary role in promoting cancer. 
Recent studies have strongly suggested that the 
relationship between obesity and T2DM and the in-
creased  risk  of  cancer  and  cancer-related  mortality 
maybe  explained  by  the  hyperinsulinemia,  particu-
larly  but  not  restricted  to  breast  cancer  (42-43). 
Whether  this  effect  is  mediated  by  the  IR  or  the 
IGF-1R, is as yet undefined, though both are capable 
of this effect  (44). However, the mechanisms which 
actually  promote  cancer  growth  in  patients  with 
metabolic syndrome demand further investigation. 
The Insulin and IGF Systems 
IGF-1 and its effects 
The IGF-1 system comprises three peptides, in-
sulin,  IGF-1,  IGF-2  and  each  with  its  receptor  (IR, 
IGF-1R, IGF-2R) as well as the IGF-binding proteins 
(IGFBPs).  Both  IGF-1  and  IGF-2  bind  the  IGF-1  re-
ceptor  with  a  high  affinity.  The  IGF-2R  is  the  cati-
on-independent  mannose-6-phosphate  receptor  and 
its  signaling  pathway,  if  any,  is  unclear  (40).  IGF-2 
was identified as being a fetal growth factor (45) in 
comparison to IGF-1, which stimulates fetal as well as 
post-natal  growth.  The  liver-derived  IGF-1  is  the 
growth promoting mediator of growth hormone (33, 
46-47). Even though the liver is the main source of the 
IGF-1  production,  non-hepatic  IGF-1,  which  is  pro-
duced  by  many  cell  types,  also  plays  an  important 
role.  Thus,  IGF-1  acts  via  endocrine,  paracrine  and 
autocrine  mechanisms  (40).  The  growth  promoting 
effects of IGF-1 include stimulation of proliferation, 
differentiation and protein synthesis and are accom-
panied by the consistent effect on cells by reducing 
apoptosis  (40).  IGF-1  also  regulates  the  cell  cycle 
through modulation of cyclins, cyclin-dependent ki-
nases  and  cyclin-dependent  kinase  inhibitors  (48). 
Tumors often express IGF-2 which is more mitogenic 
than IGF-1 and signals via the IGF-1R and the mito-
genic subtype of the IR, IR-A (49). Int. J. Biol. Sci. 2011, 7 
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IGF-2 
As with insulin and IGF-1, the overexpression of 
IGF-2  is  also  associated  with  cancer  development. 
Like IGF-1 it is mainly expressed by the liver but also 
by other tissues in adult humans. Its regulation is car-
ried out by genetic imprinting. Reduced methylation 
of the differentially methylated region (DMR) on the 
maternal allele leads to an overexpression of IGF-2. 
Thus,  a  loss  of  imprinting  and  overexpression  of 
IGF-2  is  observed  in  many  tumors.  Furthermore, 
IGF-2 initiates endocytosis of its bound IGF-2R and 
thus leads to a clearance of IGF-2 (50).  
IGF-binding proteins (IGFBPs)  
There are six IGFBPs showing different charac-
teristics  and  functions.  They  bind  IGF-1  and  IGF-2 
with a higher affinity than the IGF-1 receptor. 99% of 
circulating IGF-1 is bound to IGFBPs and 80% thereof 
to IGFBP-3 (40). IGFBPs are produced by the liver and 
most tissues and can be found in the circulation as 
well as the extracellular compartments. They are able 
to inhibit or stimulate the effects of IGFs and display 
IGF-independent  effects  (37).  They  enhance  the 
half-life  of  the  IGF-1  and  IGF-2,  protect  them  from 
degradation  and  regulate  their  bioavailability  and 
their  release  to  the  target  cells  (40).  IGFBP-2  was 
found to suppress the tumor suppressor gene product 
PTEN  in  MCF-7  breast  cancer  cell  lines.  The  phos-
phatase PTEN induces reduction of protein synthesis 
and cell cycle progression and antagonizes the PI3K 
pathway  and  in  IGF-2  signaling  (50).  IGFBP-3  has 
protective  effects  against  cancer  development.  It  is 
up-regulated by p53 and might either promote apop-
tosis through a p53-dependent mechanism or through 
binding a putative IGFBP-3 receptor, which mediates 
its  anti-apoptotic  effects  through  caspase-8  (51). 
IGFBP-3 also might have a protective impact because 
of its strong affinity and thus slow release of IGF-1 
and IGF-2 to the receptor. Hyperinsulinemia and in-
creased levels of IGF-1 lead to a decreased secretion of 
GH  and  thus  secondarily  leads  to  less  IGFBP-3  ex-
pression.  This  might  cause  an  increased  IGF-1  sig-
naling  and  a  reduction  of  the  apoptosis  promoting 
effects of IGFBP-3 (50).  
 
 
Figure 1. The insulin receptor (IR) with its two subtypes IR-A and IR-B, the insulin growth factor 1 receptor (IGF-IR) and 
the hybrid receptors (IGF-1R/IR-A and IGF-1R/IR-B). Structurally, IR and the IGF-1R have two extracellular -subunits and 
two transmembrane -subunits that are jointed to each other by disulfide bonds. Affinity, insulin binds with high affinity to 
IR-A or IR-B but has low affinity for IGF-1R, while insulin has no binding to the hybrid receptors. IGF-1 binds to the IGF-1R 
and to the hybrid receptor IGF-1R/IR-A or IGF-1R/IR-B. IGF-2 binds to IR-A, IGF-1R or to IGF-1R/IR-A hybrid receptor. 
Signaling, ligand binding to insulin receptor-A or to IGF-1 receptor mediates the mitogenic signaling pathway, while ligand 
binding to insulin receptor-B activates metabolic signaling. Binding to the hybrid receptors, leading to mitogenic or metabolic 
signaling, is determined by the IR isoform that formed the hybrid receptors. Reproduced by permission of the RMMJ (54). Int. J. Biol. Sci. 2011, 7 
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The insulin receptor and IGF-1 receptors 
Both the IR and the IGF-1R are transmembrane 
oligomer receptors which consist of one α- and one 
-subunit. The -subunit comprises a tyrosine kinase 
which  undergoes  autophosphorylation  after  the  lig-
and binds to the extracellular α-subunit of the recep-
tor.  Subsequently  insulin  receptor  substrates  and 
adaptor proteins are recruited, activated and induce 
two major signaling pathways. On one hand the mi-
togenic MAPK pathway and on the other hand the 
metabolic  and  anti-apoptotic  PI3K  pathway.  The 
MAPK pathway plays in important role in cell growth 
and proliferation. The anti-apoptotic influence of the 
PI3K pathway is mediated through the activation of 
protein kinase B (AKT) which controls among other 
things apoptosis-regulating transcriptions factors (40). 
Cells  that  express  the  IR  and  the  IGF-1R  may  also 
form a hybrid receptor from two subunits of these two 
receptors. Insulin manifests a decreased affinity to the 
IGF-1R and a very low affinity to the hybrid receptors. 
However IGF-1 retains its high affinity to the IGF-1R 
as well as to the hybrid receptors. Since there are two 
subtypes of the IR, the IR-A and the IR-B, there also 
exist two different hybrid receptors of IGF-1 and IR 
(IGF-1/IR-A, IGF-1/IR-B). As the IR-A homoreceptor, 
the  IGF-1R/IR-A  hybrid  receptor  mainly  results  in 
mitogenic signalling. Comparatively the IGF-1R/IR-B 
hybrid receptor results in metabolic signaling (37, 52). 
The IR-A receptor has been seen to be aberrantly ex-
pressed especially in fetal cells and many tumor cells 
and it additionally has a high affinity to IGF-2, com-
pared to IR-B. This may explain why hyperinsuline-
mia  has  a  cancer-promoting  effect  in  diabetic  and 
obese  patients.  The  IR-B  receptor  is  predominantly 
expressed by the liver, muscle and adipocytes, which 
generally  causes  metabolic  signaling  in  adult, 
well-differentiated tissues (53). Furthermore, studies 
found an up-regulation of IR splicing in insulin target 
tissues of patients with insulin resistance. However, 
its role in type 2 diabetes is not as yet well understood 
(53).  
IGF-1 receptor signaling and its potential link 
to cancer development 
The IR and the IGF-1R are able to mediate their 
effects  through  recruitment,  phosphorylation  and 
thus  activation  of  IRS-1,  Shc,  Grb2,  Ras  and  subse-
quent of PI3K, AKT and mTOR or Raf-1, MAPK/ERK. 
In the following we try to clarify some potential link-
ing points of the IGF-1R signaling cascades to cancer 
development.  
mTOR and PI3K 
PI3K signaling activates Akt resulting in activa-
tion of mTOR and thus, mediating its effects on cell 
growth by increasing ribosomal protein synthesis and 
preparation  of  mitosis  through  S6k1  and  4E-BP-1. 
Activation of mTOR results in protein synthesis, cell 
growth  and  the  preparation  of  cells  for  mitosis,  all 
mechanisms that favor tumor growth (50). Dysregu-
lated signaling of mTOR has been linked to numerous 
human cancers (56). Apart from that, mTOR plays an 
important role in mediating the signaling of insulin, 
growth factors, nutrients and energy. A homozygous 
deletion of the mTOR target S6K1 (ribosomal protein 
S6 kinase 1) in mice was found to lead to hyperinsu-
linemia and glucose intolerance (58).  
mTOR and TSC 
mTOR regulation is controlled not just by PTEN 
but also by the tumor suppressor gene products tu-
berous sclerosis (TSC) 1 and TSC-2. These two pro-
teins together form the Tuberous Sclerosis Complex 
(TSC)  and  incorporate  and  transfer  cellular  growth 
factor and stress signals to negatively regulate TOR 
activity  (56).  TSC-1  and  TSC-2  receive  input  from 
several  signaling  pathways  like  the  PI3K, 
LKB1-AMPK, MAPK and in response to hypoxia. Ac-
tivated AKT leads to a phosphorylation of TSC-2 re-
nouncing its inhibitory influence on mTOR through 
the  small  GTPase  Ras-homolog-enriched-in-brain 
(Rheb)  (50).  mTOR  stimulating  activity  of  Rheb  is 
regulated  by  TSC-1  and  TSC-2.  Whether  TSC-1  or 
TSC-2 mediates cell growth promoting or inhibiting 
effects,  depends  on  its  upstream  signaling  cascade 
and  which  of  the  four  binding  sites  of  TSC  gets 
phosphorylated. AKT results in an inhibition of TSC-2 
and thus, relieves the inhibition on mTOR, in which 
AMPK seems to mediate stimulating effects on TSC. 
AMPK interacts through phosphorylation with TSC-2 
as well as with mTOR and thus is capable of inhibit-
ing the activation of mTOR by a direct and indirect 
way. The detailed mechanism of the AMPK-TSC in-
teraction is not clear (59).  
mTOR regulation 
Insulin resistance leads to a decreased entry of 
glucose  into  cells  and  consequently  results  conse-
quently  in  a  deprivation  of  energy.  Therefore  the 
concentration  of  the  high-energy  compound  ATP 
drops and AMP rises. An enhanced concentration of 
AMP shows a low energy level of the cell and leads to 
activation of AMPK, which is controlled by the tumor 
suppressor  gene  LKB1.  Basically,  AMPK  activation Int. J. Biol. Sci. 2011, 7 
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results in inactivation of mTOR, thereby preventing 
protein production, cell growth and proliferation (50). 
mTOR was found not just to be inhibited by energy 
depletion but also by hypoxia. The TSC-1/TSC-2 tu-
mor  suppressor  complex  inhibits  mTOR  and  also 
regulates accumulation of HIF-. Tsc-2-deficient cells 
did not influence up-regulation of HIF- in response 
to  hypoxia,  whereas  Tsc2+/+  cells  down-regulated 
HIF- with prolonged hypoxia. LKB1 and AMPK are 
not involved in inhibition of mTOR in hypoxia but 
this is achieved by REDD1 (regulated in development 
and  DNA  damage  responses  1)  (55).  The  stress  re-
sponse gene REDD1 is induced by hypoxia and en-
ergy stress. REDD1-deficient cells manifest a highly 
defective TOR regulation in response to either of these 
stress  signals  (56).  REDD1  mRNA  was  found  to  be 
induced by hypoxia. However, how mechanistically 
REDD1 interacts with TSC is not known yet but its 
significance  in  inhibiting  mTOR  in  hypoxia  is  clear 
(55). Since it is known that hypoxic TSC-2-deficient 
cells demonstrate high levels of cell proliferation, it 
seems to be important in hypoxia to inhibit mTOR to 
prevent tumor development.  
 
Figure 2. Insulin-like growth factor 1 receptor (IGF-1R) signaling pathway. ( "->" : activation, "-●": inhibition). Binding of 
IGF-1 or IGF-2 or insulin to the IGF-1R α-subunit leads to autophosphorylation of β-subunit residues, which then act as 
docking site to insulin receptor substrates (IRS-1 to 4). Bound IRS-1 results in PI3K activation, which in turn activates Akt. 
The tumor suppressor phosphates and tensin homolog deleted on chromosome 10 (PTEN) inhibits PI3K. Activated Akt has 
many substrates; in one pathway Akt inhibits apoptosis by inactivating BCL-2 antagonist of cell death (BAD), and in the 
second pathway Akt regulates protein synthesis by phosphorylating tuberous sclerosis complex (TSC1/2). This phosphor-
ylation removes the inhibition of TSC from mammalian target of rapamycin (mTOR). mTOR activates the ribosomal S6 
kinase (S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP-1), leading to protein synthesis. In energy depletion 
expression of the suppressor gene LKB1 and AMP raise. AMPK is activated by both mechanisms. AMPK inhibits protein 
synthesis through direct inhibition of mTOR or indirectly by activating the TSC complex. Hypoxia induces REDD1. The 
detailed interaction between REDD1 and TSC is not clear yet. We conclude that the inhibition of HIF- by TSC might be 
independent of REDD1. The mitogen-activated protein kinase (MAPK) pathway can also be activated by IGF-1R activation. 
In this pathway IGF-1R activates the adaptor proteins, Shc and Grb2, leading to activation of Ras, Raf, MEK1/2, and ERK1/2, 
which results in cell proliferation. Int. J. Biol. Sci. 2011, 7 
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PTEN, MAPK and PI3K 
PTEN is, after p53, the most commonly mutated 
tumor suppressor gene in human cancer. A mutation 
or inactivation of at least one copy of PTEN emerges 
in more than 50% of women breast cancer. In MCF-7 
breast cancer cells it has  been shown that a loss of 
PTEN results in an increased signaling of IGF-2 me-
diating  through  the  IGF-1R  and  IR-A  (57).  Another 
mechanism whereby PTEN counters cell growth and 
cell  cycle  progression  is  to  inactivate  PI3K  by 
dephosphorylation.  
PI3K and MAPK 
One example for a cancer cell line which hosts a 
mutation of a kinase of the IGF-1R signaling cascade is 
the MET-1 breast cancer cells overexpressing polyoma 
virus middle T antigen (PyVmT). When stimulated by 
insulin  or  IGF-1,  MET-1  breast  cancer  cells  overex-
pressing  PyVmT  and  thus  actually  inducing  PI3K, 
have been observed to demonstrate an increased in-
teraction  with  Src  and  PLC1  (50,  60).  Src  initiates 
MAPK pathway resulting in cell proliferation and is 
known,  like  phospholipase  C1  (PLC1),  to  induce 
tumor growth (50). 
It  is  conceivable  that  a  mutation  of  the  tumor 
suppressor genes PTEN and/or TSC, combined with 
hyperinsulinemia and an increased signaling of insu-
lin and/or IGF-1 might promote tumor growth. Fur-
thermore, non-functional and dysfunctional IGF-1Rs 
were  shown  to  inhibit  growth  of  lung  cancer  and 
Ewing sarcoma cell lines and to decrease proliferation 
in mammary glands in mice. Additionally, breast and 
prostate  cancer  cell  lines  were  found  to  display  an 
enhanced level of IGF-1R and decreased level of IR 
(50). This data provide strong support for the signifi-
cance of the IGF-1R and/or IR signaling for cancer 
development and growth. 
IGF-1R and regulation of apoptosis 
IGF-1 through the IGF-1R affects the apoptotic 
machinery at several levels. It is capable of mediating 
both anti-apoptotic and pro-apoptotic effects but acts 
mainly  anti-apoptotic.  By  activation  of  PI3K-AKT 
pathway,  IGF-1  may  indirectly  inactivate  caspase-9 
through  phosphorylation  and  thus  realize  its  an-
ti-apoptotic effects. IGF-1 inhibits the intrinsic path-
way  by  initiating  phosphorylation  of  Bcl-2  family 
proteins  like  BAD.  IGF-1  also  controls  the  extrinsic 
apoptotic  pathway  via  regulation  of  the 
death-inducing  receptor.  IGF-1  regulates  multiple 
transcription factors like CREB, FKHR, NF-B, mdm2 
and  p53,  which  are  involved  in  the  regulation  of 
apoptotic proteins. It is known that IGF-1 mediates its 
effects  through  different  signaling  cascades  such  as 
MEK-ERK,  14.4.4-raf,  PI3K-AKT  and 
p38-MAPKAP-K3. It is conceivable that in some cell 
types it might be necessary to activate multiple sig-
naling  pathways  at  once  to  reach  full  protection 
against  apoptosis.  By  being  capable  of  mediating 
through  many  different  signaling  pathways  the 
IGF-1R may be able to protect cells against multiple 
apoptotic factors. However, which pathway is used 
by  the  IGF-1R  to  inhibit  apoptosis  depends  on  the 
specific cell type (40).  
Interaction of causal factors involved in the 
connection between Diabetes and Obesity 
and Cancer 
Diabetes and the increased resistance against 
therapeutic agents 
It has been observed that patients with diabetes 
tend to show impaired response to cancer treatment 
(10).  By  a  variety  of  mechanisms  an  aberrant  mito-
genic IR-A expression may favor cancer resistance to 
both conventional and targeted therapies (53). A re-
sistance to chemotherapeutic agents like trastuzumab 
and tamoxifen in breast cancer cell lines was associ-
ated  with  an  activation  of  mTOR.  One  activator  of 
mTOR and thus promotor of cell growth and prolif-
eration is displayed by AKT. Interestingly, Metformin 
was found to activate AMPK and decrease AKT and 
insulin levels in mice (61). Both mechanisms result in 
a decreased signaling of cell growth. This might ex-
plain why Metformin is associated with a decreased 
risk of cancer development and a better response to 
chemotherapy in patients with breast cancer (50). 
Connection between obesity, insulin, IGF-1 
and cancer development 
Compared  to  normal-weight  individuals  the 
augmented adipose tissue in obesity produces an in-
creased amount of FFAs, triglycerides, leptin and in-
flammatory  cytokines.  These  metabolic  changes, 
combined  with  reduced  physical  activity  raise  the 
secretion  of  insulin.  This  mechanism  results  in  hy-
perinsulinemia and insulin resistance common in the 
pre-diabetic condition.  
The liver seems to be the main source providing 
75% of the circulating IGF-1 (40). The hepatic IGF-1 
production is dependent on the signaling of growth 
hormone (GH) mediated by the growth hormone re-
ceptor  (GHR).  Obesity  and  hyperinsulinemia  are 
known to influence the level of GH and as a result of 
IGF-1. Hyperinsulinemia was also found to stimulate Int. J. Biol. Sci. 2011, 7 
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the expression of the growth hormone receptor (GHR) 
in the liver tissue. Thus it is comprehensible that hy-
perinsulinemia  and  obesity  cause  an  increased  pro-
duction of hepatic IGF-1 by a enhanced signaling of 
the GHR in the liver. This in turn, raises the amount of 
circulating IGF-1 and therefore results in cell growth 
and proliferation (62-63).  
Estrogen, obesity and breast cancer 
The enhanced percentage of fat tissue in obesity 
delivers an augmented level of aromatase, which re-
sults in an increased synthesis of estrogen. Further-
more,  obesity  as  well  as  hyperinsulinemia  and  ele-
vated IGF-1 levels were shown to reduce the produc-
tion  of  sex  hormone-binding  globulin  (SHBG).  This 
also leads to an increased bioavailability of estrogen 
(63). It was shown that the pathways of the IGF-1R 
and the estrogen receptor (ER) synergize in the acti-
vation  of  the  mitogen-activated  protein  kinase 
(MAPK).  Estrogen  was  demonstrated  to  induce  the 
expression of the IGF-1R as well as the insulin recep-
tor substrates IRS-1 and IRS-2. These effects of estro-
gen  led  to  an  enhanced  IRS-1  phosphorylation  and 
hence  an  increased  activation  of  MAPK  after  IGF-1 
stimulation of MCF-7 breast tumor cells (64). Leptin 
and insulin as well as TNF-α and IL-6 are known to 
induce  aromatase  and  thus  stimulate  estrogen  bio-
synthesis  (65).  These  results  might  explain  the  con-
nection  of  the  enhanced  growth  of  breast  cancer  in 
patients with T2DM and obesity.  
Additional factors 
Leptin 
The major source of leptin is the white adipose 
tissue but it can also be secreted by cells of the pla-
centa,  ovaries,  mammary  epithelial,  brown  adipose 
tissue,  skeletal  muscle,  the  fundal  glands  of  the 
stomach, bone marrow, pituitary and the liver  (66). 
Leptin mediates the feeling of satiety through its re-
ceptors in the hypothalamus. The absence of leptin as 
well as a dysfunction of the leptin receptor results in 
an uncontrolled food intake and obesity (67). Leptin 
as well as insulin levels in the plasma were positively 
correlated with body weight and especially with the 
adipose mass (68). However, obese people were found 
to  manifest  high  leptin  levels  in  the  plasma  and 
demonstrate leptin resistance (69). Leptin was found 
to improve insulin resistance and hyperglycemia by 
increasing the hepatic responsiveness to insulin and 
thus most likely decreasing the gluconeogenesis of the 
liver.  In  this  study,  they  further  observed  an  im-
provement of the lipotoxic condition through an in-
creased  fatty  acid  oxidation  and  inhibition  of  the 
liponeogenesis that led to a reduction of lipid stores in 
liver  and  muscles  (70).  Leptin  might  be  associated 
with cancer cell proliferation in colorectal cancer as 
well  as  acute  myeloid  leukemia  and  was  found  to 
reduce  apoptosis  by  mediating  cytokines  in  MO7E 
and TF-1 cells. Similarly in cancer cell lines of esoph-
ageal, breast and prostate cancer leptin was seen to 
stimulate cellular proliferation (71-72). A breast cancer 
study  showed  that  leptin  up-regulates  VEGF  and 
found that leptin mainly requires activation of HIF-1α 
and  NF-B  for  its  regulation  of  VEGF  (73).  Other 
studies suggest that hypoxia might lead to a secretion 
of leptin by adipocytes which is induced by HIF-1α 
(31). However, it still requires further investigation to 
determine the specific role of leptin in cancer devel-
opment.  
Adiponectin 
Adiponectin is a protein, which is produced of 
the  adipocytes  and  regulates  energy  homeostasis, 
glucose  and  lipid  metabolism  (74-75).  It  has  an-
ti-inflammatory characteristics and was found to be 
decreased in obese individuals and elevated in nor-
mal-weight  people  (5).  In  adults  the  level  of  adi-
ponectin is inversely associated to the percentage of 
body fat even though it was shown to be the most 
abundantly  expressed  protein  in  the  adipose  tissue 
(76). Loss of weight in turn results in a significant rise 
of adiponectin concentration in the blood circulation 
(77).  Some  studies  suggest  a  decreased  adiponectin 
production secondary to adipose tissue hypoxia. They 
found that hypoxia induces expression of inflamma-
tory cytokines and concurrently reduces the mRNA of 
adiponectin. Furthermore it was shown that the gene 
promotor activity of adiponectin was down-regulated 
by hypoxia and TNFα. Since it is known, that TNFα 
might reduce adiponectin mRNA levels, it is not clear 
if  hypoxia  realizes  its  effects  in  a  direct  manner  or 
through  TNFα  (31,  78-80).  Furthermore,  women 
demonstrate a higher level of adiponectin than men 
(77). Adiponectin also correlates with systemic insulin 
sensitivity (81) and was found to be reduced in dia-
betic  patients  compared  to  healthy  individuals.  Its 
insulin-sensitizing  effects  are  mediated  through  its 
two receptors Adipo R1 and Adipo R2 (82). By acti-
vation of AMP-activated protein kinase (AMPK) and 
thus indirectly suppressing mTOR, adiponectin was 
found to inhibit colorectal cancer cell growth (83). By 
using the AMPK pathway, adiponectin also affects the 
regulation of glucose utilization and fatty-acid oxida-
tion (5, 75, 84-85). Adiponectin is considered to have 
anticancer  effects  because  of  its  anti-inflammatory 
character and further was found to be a negative reg-
ulator of angiogenesis (86). It was shown that addition Int. J. Biol. Sci. 2011, 7 
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of  adiponectin  to  gastric  cancer  cell  lines  inhibited 
their proliferation. A continuous intraperitoneal infu-
sion  of  adiponectin  succeeded  in  suppressing  the 
formation of peritoneal metastasis (87). 
Inflammatory Factors 
Hyperinsulinemia,  obesity  and  hypoxia  are 
linked to inflammation and cancer development. The 
elevated levels inflammatory cytokines produced by 
macrophages and adipocytes within the adipose tis-
sue include IL-6 and TNF-α (5, 84, 88). Cytokines are 
considered  to  form  one  link  between  inflammation 
and cancer. Cancer causing mechanisms like a loss of 
tumor  suppressor  function,  increase  of  cell  cycling 
and stimulation of oncogene expression were found to 
be related to cytokines, reactive oxygen species (ROS) 
and mediators of the inflammatory pathways (TNF-α, 
COX-2) (3). 
IL-6 
IL-6  and  TNF-α  are  known  to  promote  angio-
genesis (65). The secretion of IL-6 by human adipo-
cytes rises significantly with the BMI (89). Enhanced 
levels  of  IL-6  were  found  in  breast  cancer  patients. 
Patients with insulin resistance showed even higher 
levels. However, highest levels of IL-6 were detected 
in patients with ER positive breast cancer. In prostate 
cancer  the  IL-6  levels  were  significantly  higher  in 
hormone-resistant  tumors  compared  to  hor-
mone-dependent  cancer  (5).  IL-6  is  correlated  with 
obesity and was additionally shown to be necessary 
for the differentiation of immature plasmablasts into 
mature antibody producing plasma cells (5). IL-6 may 
explain the association of B cell lymphoma and mul-
tiple myeloma which are increased in obesity.  
TNF-α  
TNF-α  is  also  causally  related  to  cancer,  acute 
sepsis  and  chronic  inflammation.  In  obesity,  it  was 
shown  that  adipocytes  and  infiltrated  macrophages 
express an increased level of TNF-α, which had been 
positively correlated with insulin resistance and waist 
circumference  (90).  TNF-α  demonstrates  apoptotic 
effects  by  inhibiting  mTOR  and  protein  synthesis 
through IB kinase (IKK) and MAPK pathways. Also 
necrotic cell death might be induced by TNF-α. Fur-
thermore, TNF-α was found to phosphorylate IRS-1 
and IRS-2 and therefore interfere in the signaling of 
the tyrosine kinase of the IR which might contribute to 
insulin resistance. TNF-α function lacking, obese mice 
even  were  shown  to  be  protected  from  developing 
insulin resistance (5, 32, 84). However, one study an-
alyzing the effects of TNF-α on myoblasts observed an 
anti-apoptotic  effect  of  TNF-α.  Treatment  of  C2C12 
myotubes with TNF-α for 24 hours led to an increase 
in protein synthesis and increased activity of cellular 
dehydrogenase  up  to  26%.  The  PI3K-Akt  and 
MEK-ERK signaling cascades were detected to be the 
activated pathways mediated by the TNF-α receptor 1 
(TNF-R1)  (91).  This  was  ascribed  by  an  enhanced 
protein synthesis also mediated through the PI3K / 
AKT  /  NF-B  and  the  MAPK  /  ERK  pathway  (5). 
However, TNF-α mediates the transcription of a vari-
ety of proteins involved in inflammation, cell surviv-
al, proliferation and prevention of apoptosis through 
its activation of NF-B pathway and MAPK pathway, 
we can conclude from this data that TNF-α also might 
have  a  protective  impact  by  improving  insulin  re-
sistance  and  thus  attenuating  its  cancer  promoting 
influence. 
CRP (C-reactive protein) 
C-reactive protein (CRP) is an acute phase pro-
tein produced and secreted mainly by the liver and a 
sensitive  unspecific  marker  for  inflammation,  infec-
tion and tissue injury. It binds to exogenous and au-
tologous  molecules  containing  phosphocholine  (PC) 
which are released from damaged cells and expressed 
on the surface of some types of bacteria. After bind-
ing, the concentration of CRP in the blood rises rap-
idly  and  extensively  and  activates  the  complement 
system (92).  
In 35% of obese men and 60% of obese women 
with a BMI > 30 kg/m2, increased levels of CRP were 
found (93). There is a close correlation between the 
proportion of CRP levels and the amount of adipose 
tissue. Given that adipose tissue secretes a remarkable 
amount  of  pro-inflammatory  mediators,  including 
IL-6, TNF-α and leptin and that IL-6 is the main reg-
ulatory cytokine of hepatic CRP synthesis, it is com-
prehensible  that  the  enhanced  amount  of  adipose 
tissue in obesity leads to an increased concentration of 
CRP. Moreover, expression of CRP was found in hu-
man, mouse and rat adipose tissue showing a twofold 
increase in obese animals, compared to lean controls 
(94). CRP and IL-6 levels were reported to predict the 
development  of  diabetes  in  both  obese  men  and 
women what identifies CRP as the potential link be-
tween obesity and diabetes (95-96). Furthermore, CRP 
is associated with an increased risk to develop colo-
rectal,  cervical  and  ovarian  cancer  (97).  These  data 
may  clarify  an  association  between  inflammation, 
T2DM, obesity and cancer.  
Transcription factors 
NF-B (nuclear factor 'kappa-light-chain- 
enhancer' of activated B-cells) 
NF-B is a transcription factor which is present Int. J. Biol. Sci. 2011, 7 
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in the cytoplasm of almost all cell types in an inactive 
state. This allows a fast response and immediate ex-
pression change to any harmful cellular stimuli. Thus, 
NF-B is activated by many factors such as several 
cytokines, reactive oxygen species (ROS), bacterial or 
viral antigens like bacterial lipopolysaccharides (LPS) 
and ionizing radiation. NF-B activates the expression 
of genes which promote cell proliferation and inhibit 
apoptosis and therefore enhances cell survival. Thus, 
it  is  not  remarkable  that  several  different  types  of 
human tumors display dysregulated NF-B function 
(98).  
HIF-1α (hypoxia inducible factor 1alpha) 
HIF-1α  is  a  transcriptional  factor,  which  is  in-
duced  by  hypoxia  and  activates  the  expression  of 
certain genes. Activation of HIF-1α relies on the oxy-
gen-dependent hydroxylation of prolyl residues and 
leads to an elevation of vascularization in tumors. In 
normoxia the HIF-1α level is regulated by ubiquitina-
tion and subsequently degradation in the proteasome 
so  that  the  half-life  of  this  protein  is  less  than  five 
minutes. An enhanced HIF-1α level results from de-
creased ubiquitination which is induced by EGF, in-
sulin and IGFs through their PI3K-AKT and MAPK 
pathways (31). The bacterial lipopolisaccharide is able 
to activate HIF-1α even in normoxic conditions which 
lead to the initiation of an inflammatory response. The 
HIF-1α  pathway  interacts  with  the  NF-B  pathway 
and  hence  links  hypoxia  to  inflammation.  Solid  tu-
mors  were  found  to  contain  enhanced  levels  of 
HIF-1α. Also oncogenes and the loss of function  of 
tumor  suppressor  genes  are  capable  of  stabilizing 
HIF-1α. These observations have been associated with 
an increased risk of metastasis and tumor invasive-
ness. Furthermore, HIF-1α inhibition might improve 
sensitivity of tumors to radiation (88). 
PPARs (Peroxisome proliferator-activated 
receptors) 
PPARs are transcription factors which belong to 
the  nuclear  hormone  receptor  superfamily  and  are 
activated  by  ligands.  One  of  three  different 
PPAR-subtypes, the PPAR, is mostly found in the 
liver and plays an important role in activation of fatty 
acid catabolism. The ubiquitously expressed PPAR 
(also  known  as  )  induces  fatty  acid  oxidation  and 
differentiation of keratinocytes. PPAR is able to im-
prove  insulin  resistance  through  its  interactions  in 
glucose metabolism whereas PPAR2 was found to be 
important  for  the  differentiation  of  adipose  tissue. 
However, several studies suggested activated PPAR 
as a anti-tumorigenic and pro-differentiation factor in 
which PPAR seems to act in a tumorigenic manner 
(3). 
Other Factors 
COX-2 (Cyclooxygenase-2) 
Many cell types produce the inducible enzyme 
COX-2. It was found to be overexpressed in several 
cancer types and linked to promotion of carcinogene-
sis  by  increasing  the  production  of  prostaglandins, 
conversion of pro-carcinogens to carcinogens, inhibi-
tion of apoptosis, promotion of angiogenesis, modu-
lation of inflammation and immune function and the 
increase of tumor cell invasiveness (3). 
MIF (macrophage migration inhibition factor) 
MIF is a target gene of HIF-1α thereby activated 
by hypoxia. MIF is secreted by macrophages, adipo-
cytes as well as lymphocytes and its effect results in a 
decreased departure of macrophages out of hypoxic 
areas in tissues. MIF was negatively correlated with 
insulin sensitivity and its level rises with the BMI. The 
detailed role of MIF is unclear but there might be a 
connection between the MIF-induced inflammation of 
adipocytes and insulin resistance and thus with can-
cer (31). 
Conclusion 
In this article we describe the effects of the met-
abolic  syndrome  (obesity  and  Type  2  diabetes)  on 
cancer development and progression. We stress that 
the  insulin  and  IGF  systems  are  important  causal 
factors in this connection. However, there are a num-
ber of other factors that may play important roles as 
well. Clearly the tumor promoting potential of the IR 
and IGF-1R might be a promising answer to identify 
major cancer promoting mechanisms, with therapeu-
tic possibilities, in such a high-prevalent disease like 
the metabolic syndrome. 
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